Abram Hoffer, MD, PhD administered gram-scale nicotinic acid (typically ~3g/day) to thousands of patients over more than 50 years of clinical practice. His records represent the largest single-practitioner dataset on high-dose nicotinic acid supplementation.
What he observed
Hoffer's clinical observations, reported across his published work, included improvements in schizophrenia, arthritis, and various inflammatory conditions. He used immediate-release nicotinic acid exclusively, noting that other forms did not produce the same effects.
His typical protocol: start at 500mg three times daily with meals, titrating up to 1g three times daily. The flush typically diminished over weeks. He observed that patients with higher inflammatory states experienced more intense initial flushing that resolved faster.
What modern research can explain
The GPR109A receptor mechanism — discovered decades after Hoffer began his work — provides a plausible molecular basis for his observations. Nicotinic acid activates GPR109A, promoting regulatory T cells and anti-inflammatory cytokines. This pathway is specific to nicotinic acid (not niacinamide or NR), consistent with Hoffer's insistence on the specific form.
The flush itself is GPR109A-mediated (via prostaglandin D2), which explains why flush intensity correlates with inflammatory state — more receptor activation needed, more PGD2 released.
What remains unexplained
His work was observational, not controlled. Selection bias, placebo effects, and concurrent treatments are all confounders. No modern RCTs have replicated his protocol at his scale. The dose-response relationship at gram-scale in humans is still poorly characterized for immune outcomes.
The reader draws their own conclusions.
See GPR109A pathway and dose-response analysis for the underlying evidence.